Viblac Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 27.04%
- Profit Growth 21.23%
- Ebitda -333.03%
- Net Worth -5.83%
- Total Assets -1.37%
About Viblac Pharma
Viblac Pharma Private Limited (VPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 February 2018 (Six years and 11 months 12 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mukesh Chaudhary, Vivek Kumar, and Rashmi Agrawal serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999DL2018PTC330176
-
Company No.
330176
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Feb 2018
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Viblac Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Chaudhary
|
Director | 28-Feb-2018 | Current |
|
Vivek Kumar
|
Director | 28-Feb-2018 | Current |
|
Rashmi Agrawal
|
Director | 28-Feb-2018 | Current |
Financial Performance of Viblac Pharma.
Viblac Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.04% increase. The company also saw a substantial improvement in profitability, with a 21.23% increase in profit. The company's net worth dipped by a decrease of 5.83%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Viblac Pharma?
Unlock access to Viblac Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Priqure Technology Private LimitedMukesh Chaudhary is a mutual person
-
Smartai India Private Limited
Mukesh Chaudhary is a mutual person
-
Rapoo Technologies India Private Limited
Mukesh Chaudhary is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Viblac Pharma?
Unlock and access historical data on people associated with Viblac Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Viblac Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Viblac Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.